Clinical trial · Observational
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying immune response to flu vaccine in patients who have undergone a stem cell transplant may help doctors plan the best treatment. PURPOSE: This clinical trial is studying flu vaccine to see how well it works in preventing infection in patients who have undergone a stem cell transplant and in healthy volunteers.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloproliferative Disorders | Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
| Myelodysplastic/Myeloproliferative Neoplasms | Myelodysplastic/Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Nonmalignant Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunoenzyme technique | Other | — | UNRESOLVED |
| Laboratory biomarker analysis | Other | — | UNRESOLVED |
| trivalent influenza vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Flu vaccine
- description
- Patients and normal volunteers who have received a flu vaccine
- interventionNames
- Biological: trivalent influenza vaccine
- Other: Immunoenzyme technique
- Other: Laboratory biomarker analysis
- label
- Non-vaccine
- description
- Patients and normal volunteers who have not received the flu vaccine
- interventionNames
- Other: Immunoenzyme technique
- Other: Laboratory biomarker analysis
Primary outcomes (1)
- measure
- Humoral and cellular memory immune responses in patients and healthy volunteers
- timeFrame
- At Day 0 and 30, 90 and 180 days after vaccine in healthy participants and also at 360 days in transplant patients . 4-5 times in the first 2 years after transplant for transplant patients not vaccinated. One time in normal participants not vaccinated.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Meets 1 of the following criteria:
* Patient at the City of Hope or Kaiser hospital who underwent prior autologous or allogeneic matched-related hematologic stem cell transplantation (HSCT) or matched-unrelated HSCT for treatment of hematological malignancies, including aplastic anemia or myelodysplastic syndromes
* Eligible (in accordance with physician's recommendation) to receive the vaccine influenza A serotypes specific for the 2006-2007 or 2007-2008 influenza season
* Eligible (in accordance with physician's recommendation) to receive the vaccine influenza A or B serotypes specific for the 2009-2010 or 2010-2011 influenza season
* Patients who are not vaccinated are followed under the study protocol once they are matched to a vaccinated patient on the date of transplant and source of transplant
* All HLA serotypes allowed
* Employee volunteer from the City of Hope
* Meets the requirements for influenza vaccination
* Eligible to receive the CDC recommended vaccine for influenza A serotypes specific for the 2007-2008 flu season as part of occupational health's vaccination initiative
* All HLA serotypes allowed
PATIENT CHARACTERISTICS:
* Life expectancy \> 9 months
* No HIV seropositivity
* No hepatitis B or C seropositivity
* Hepatitis B-positive serology by vaccination allowed
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior influenza vaccination after transplantationReferences
Publications (0)
Data not yet available